Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [¹⁸F] Florbetapir PET Brain Scan Interpretation

REFERENCES

1. 1.↵
   Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013;9:208–45

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Holtzman DM,
   3. Morris JC,
   4. Goate AM

   . Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011;3:77sr1

   FREE Full Text
3. 3.↵
   2. Hiltunen M,
   3. van Groen T,
   4. Jolkkonen J

   . Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: evidence from experimental studies. J Alzheimers Dis 2009;18:401–12

   PubMed
4. 4.↵
   2. Löppönen M,
   3. Raiha I,
   4. Isoaho R, et al

   . Diagnosing cognitive impairment and dementia in primary health care: a more active approach is needed. Age Ageing 2003;32:606–12

   Abstract/FREE Full Text
5. 5.↵
   2. Clark CM,
   3. Schneider JA,
   4. Bedell BJ, et al

   . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275–83

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Wong DF,
   3. Rosenberg PB,
   4. Zhou Y, et al

   . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913–20

   Abstract/FREE Full Text
7. 7.↵
   2. Clark CM,
   3. Pontecorvo MJ,
   4. Beach TG, et al

   . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012;11:669–78

   CrossRefPubMedWeb of Science
8. 8.↵
   FDA advisory committee briefing document: Peripheral and Central Nervous Systems Drugs Advisory Committee—draft clinical review. December 20, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240265.pdf. Accessed September 12, 2013.
9. 9.↵
   FDA approves imaging drug Amyvid. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm299678.htm. Accessed September 14, 2013.
10. 10.↵
    FDA approves 18F-florbetapir PET agent. J Nucl Med 2012;53:15N

    FREE Full Text
11. 11.↵
    2. Braak H,
    3. Braak E

    . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Fleisher AS,
    3. Chen K,
    4. Liu X, et al

    . Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011;68:1404–11

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Johnson KA,
    3. Sperling RA,
    4. Gidicsin CM, et al

    . Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013;9:S72–83

    CrossRefPubMed
14. 14.↵
    Avid Radiopharmaceuticals. Amyvid Reader Training. 2012. http://amyvidtraining.com/. Accessed June 14, 2013.
15. 15.↵
    2. Petersen R,
    3. Weiner M

    . ADNI 2 Procedures Manual. 2008. http://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf. Accessed June 14, 2013.
16. 16.↵
    2. Ghosh P,
    3. Sorger P,
    4. Buelau A, et al

    . White paper: quantitative software evaluation of amyloid brain PET imaging in dementia. 2012. http://www.healthcare.siemens.com/siemens_hwem-hwem_ssxa_websites-context-root/wcm/idc/groups/public/@global/@imaging/@molecular/documents/download/mdaw/mji1/∼edisp/whitepaper15_amyloiddementia-00274875.pdf. Accessed October 15, 2013.
17. 17.↵
    2. Camus V,
    3. Payoux P,
    4. Barre L, et al

    . Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012;39:621–31

    CrossRefPubMed
18. 18.↵
    2. Peyrat J,
    3. Joshi AD,
    4. Mintun MA, et al

    . An automatic method for the quantification of uptake with florbetapir imaging. J Nucl Med 2012;53(suppl 1):210
19. 19.↵
    2. Joshi AD,
    3. Pontecorvo MJ,
    4. Clark CM, et al

    . Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012;53:378–84

    Abstract/FREE Full Text
20. 20.↵
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2011
21. 21.↵
    2. Gamer M,
    3. Lemon J,
    4. Fellows I, et al

    . The irr package, Ver. 0.83: various coefficients of interrater reliability and agreement. 2010. http://cran.r-project.org/web/packages/irr/index.html. Accessed April 1, 2013.
22. 22.↵
    2. Vanbelle S,
    3. Albert A

    . A bootstrap method for comparing correlated kappa coefficients. Journal of Statistical Computing and Simulation 2008;78:1009–15

    CrossRef
23. 23.↵
    2. Landis JR,
    3. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Ranginwala NA,
    3. Hynan LS,
    4. Weiner MF, et al

    . Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry 2008;16:384–88

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Johnson KA,
    3. Minoshima S,
    4. Bohnen NI, et al

    . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 2013;54:476–90

    Abstract/FREE Full Text
26. 26.↵
    2. Ng S,
    3. Villemagne VL,
    4. Berlangieri S, et al

    . Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007;48:547–52

    Abstract/FREE Full Text
27. 27.↵
    2. Jeon KN,
    3. Goo JM,
    4. Lee CH, et al

    . Computer-aided nodule detection and volumetry to reduce variability between radiologists in the interpretation of lung nodules at low-dose screening computed tomography. Invest Radiol 2012;47:457–61

    CrossRefPubMed
28. 28.↵
    2. Gierada DS,
    3. Pilgram TK,
    4. Ford M, et al

    . Lung cancer: interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. Radiology 2008;246:265–72

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Wojcinski S,
    3. Gyapong S,
    4. Farrokh A, et al

    . Diagnostic performance and inter-observer concordance in lesion detection with the automated breast volume scanner (ABVS). BMC Med Imaging 2013;13:36

    CrossRefPubMed
30. 30.↵
    2. Rosario BL,
    3. Weissfeld LA,
    4. Laymon CM, et al

    . Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage 2011;55:933–41

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Luo P,
    3. Qian W,
    4. Romilly P

    . CAD-aided mammogram training. Acad Radiol 2005;12:1039–48

    CrossRefPubMed
32. 32.↵
    2. Beach TG,
    3. Monsell SE,
    4. Phillips LE, et al

    . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 2012;71:266–73

    CrossRefPubMed
33. 33.↵
    2. Lim A,
    3. Tsuang D,
    4. Kukull W, et al

    . Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 1999;47:564–69

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Bennett DA,
    3. Schneider JA,
    4. Bienias JL, et al

    . Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005;64:834–41

    CrossRefPubMed
35. 35.↵
    2. Gearing M,
    3. Schneider JA,
    4. Rebeck GW, et al

    . Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Neurology 1995;45:1985–90

    CrossRefPubMed
36. 36.↵
    2. Morishima-Kawashima M,
    3. Oshima N,
    4. Ogata H, et al

    . Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 2000;157:2093–99

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Doraiswamy PM,
    3. Sperling RA,
    4. Coleman RE, et al

    . Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636–44

    CrossRefPubMed
38. 38.↵
    2. Doraiswamy PM,
    3. Sperling RA,
    4. Johnson K, et al

    . Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry 2014;19:1044–51

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Kitazono MT,
    3. Lau CT,
    4. Parada AN, et al

    . Differentiation of pleural effusions from parenchymal opacities: accuracy of bedside chest radiography. AJR Am J Roentgenol 2010;194:407–12

    CrossRefPubMed
40. 40.↵
    2. Muyoyeta M,
    3. Maduskar P,
    4. Moyo M, et al

    . The sensitivity and specificity of using a computer aided diagnosis program for automatically scoring chest X-rays of presumptive TB patients compared with Xpert MTB/RIF in Lusaka Zambia. PLoS One 2014;9:e93757

    CrossRefPubMed
41. 41.↵
    2. Owrangi AM,
    3. Entwistle B,
    4. Lu A, et al

    . Semi-automated scoring of pulmonary emphysema from X-ray CT: trainee reproducibility and accuracy. Eur J Radiol 2013;82:e734–41

    CrossRefPubMed
42. 42.↵
    2. Pinto LM,
    3. Dheda K,
    4. Theron G, et al

    . Development of a simple reliable radiographic scoring system to aid the diagnosis of pulmonary tuberculosis. PLoS One 2013;8:e54235

    CrossRefPubMed
43. 43.↵
    2. Xie X,
    3. Zhao Y,
    4. Snijder RA, et al

    . Sensitivity and accuracy of volumetry of pulmonary nodules on low-dose 16- and 64-row multi-detector CT: an anthropomorphic phantom study. Eur Radiol 2013;23:139–47

    CrossRefPubMed
44. 44.↵
    2. Carton AK,
    3. Gavenonis SC,
    4. Currivan JA, et al

    . Dual-energy contrast-enhanced digital breast tomosynthesis: a feasibility study. Br J Radiol 2010;83:344–50

    Abstract/FREE Full Text
45. 45.↵
    2. Tagliafico A,
    3. Tagliafico G,
    4. Tosto S, et al

    . Mammographic density estimation: comparison among BI-RADS categories, a semi-automated software and a fully automated one. Breast 2009;18:35–40

    CrossRefPubMed
46. 46.↵
    2. Takeda K,
    3. Kanao S,
    4. Okada T, et al

    . Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy. Eur J Radiol 2012;81:2627–31

    CrossRefPubMed
47. 47.↵
    2. Barthel H,
    3. Luthardt J,
    4. Becker G, et al

    . Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 2011;38:1702–14

    CrossRefPubMed